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Summary
Background and objectives Chronic kidney disease (CKD) conveys high mortality rates. Soluble TNF-like
weak inducer of apoptosis (sTWEAK) and long pentraxin 3 (PTX3) are predictors of mortality in dialysis
patients and determinants of endothelial dysfunction. Now, we hypothesize that both sTWEAK and PTX3
act as biomarkers of cardiovascular outcomes in nondialysis CKD patients.
Design, setting, participants, & measurements Cross-sectional analysis in which flow-mediated dilation
(FMD) and intima-media thickness (IMT) were assessed in 257 nondialysis stage 1 to 5 CKD patients (mean
age, 52  12 years; 130 men), together with biochemical measurements and sTWEAK and PTX3 assess-
ments. Patients were followed for cardiovascular outcomes.
Results PTX3 and IMT increased, whereas FMD and sTWEAK decreased across CKD stages (P  0.001 for
all). Both PTX3 and sTWEAK appeared as strong determinants of FMD in multivariate analysis. The uni-
variate associations of sTWEAK and PTX3 with IMT were dependent on estimated GFR. After a median of
39 months (range, 2 to 43 months), 22 fatal and 57 nonfatal cardiovascular events occurred. In a Cox model
excluding PTX3, decreasing sTWEAK concentration was associated with increased risk of cardiovascular
events independently of basic confounders (age, gender, estimated GFR, C reactive protein, diabetes, and
cardiovascular comorbidity) and FMD. In a model excluding sTWEAK, circulating levels of PTX3 were di-
rectly associated with cardiovascular outcomes independently of basic confounders, but this association
was lost after adjustment for FMD.
Conclusions Both PTX3 and sTWEAK levels associated with the endothelial dysfunction observed with pro-
gressive kidney failure. Additionally, both biomarkers impacted the predictability of cardiovascular
outcomes.
Clin J Am Soc Nephrol 6: 785–792, 2011. doi: 10.2215/CJN.09231010
Introduction
Chronic kidney disease (CKD) patients die at a
markedly accelerated rate, principally from cardio-
vascular disease (CVD) (1). Progression toward
ESRD exposes patients to increased risk of devel-
oping premature vascular disease and cardiovascu-
lar morbidity, thus contributing to exceedingly high
mortality rates (2). In fact, CVD and death are more
likely outcomes in subjects with CKD than progres-
sion to ESRD and subsequent initiation of renal
replacement therapy (3). The mechanisms for the
elevated CVD risk in CKD are complex and may
involve changes in both the heart and vasculature
already at early stages. Of these, endothelial dys-
function increases in prevalence as renal function
declines and is considered a prodromal phase in the
atherosclerosis that precedes cardiovascular com-
plications (4,5). The etiology of endothelial dysfunc-
tion in CKD is likely multifaceted, involving the dys-
regulation of various pathways.
One of these pathways could be mediated by the
TNF-like weak inducer of apoptosis (TWEAK,
TNFSF12), a ubiquitously expressed type II trans-
membrane glycoprotein of the TNF superfamily that
circulates in plasma as a soluble form (sTWEAK) with
a molecular mass of 18 kD (6). Binding of TWEAK to
its receptor, Fn14, mediates multiple biologic effects
such as cellular growth, proliferation and migration,
osteoclastogenesis, angiogenesis, and apoptosis (6).
We have shown that sTWEAK plasma levels in non-
diabetic nondialysis CKD stages decrease with pro-
gressive loss in kidney function and associate with the
aggravation of the endothelial function (7). Further-
more, sTWEAK and IL-6 showed additive effects on
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mortality prediction in patients undergoing hemodialysis
(8). It is, however, unknown whether sTWEAK levels are
effective predictors of (cardiovascular) outcomes in early
and moderate nondialysis CKD stages.
Another potential dysregulated pathway in CKD-
associated endothelial dysfunction may involve long
pentraxin 3 (PTX3), a multimeric mediator that shares
structural homology with hepatic short pentraxins such
as C-reactive protein (CRP) and serum amyloid P com-
ponent, but that it is expressed by many cell types,
especially in the vasculature (9–12), in response to injury
and stress. PTX3 levels are increased in individuals un-
dergoing hemodialysis, contributing to increase both the
cardiovascular and mortality risk by pathways indepen-
dent of its homologous CRP (13,14). In type 2 diabetic
individuals with proteinuria but normal renal function, we
reported strong independent links between PTX3, endo-
thelial dysfunction, and albuminuria (15). Presently, the
association of PTX3 levels with kidney function decline
and its potential as surrogate biomarker of endothelial
function and outcome in predialysis CKD patients are
unknown.
The aims of this study are therefore multiple: first, we
wanted to confirm the usefulness of sTWEAK as a bio-
marker of endothelial function (as assessed by flow-medi-
ated dilation [FMD] assessments) and to study the course
of PTX3 levels with endothelial dysfunction and progres-
sive loss in kidney function; second, we wanted to test the
ability of circulating sTWEAK and PTX3 to predict cardio-
vascular outcomes in nondialysis CKD; finally, because
both sTWEAK and PTX3 are found present in atheroma-
tous plaques (16,17) and because arterial thickening also
occurs in parallel with kidney function loss (18), we
wanted to find the relative contribution of these molecules
to the variance of arterial thickening as assessed by carotid
intima-media thickness (IMT) measurements. We tested
this in a large cohort of etiologically diagnosed CKD pa-
tients uniformly distributed and balanced across different
disease stages.
Materials and Methods
Patients
The ethical committee of Gulhane School of Medicine
(Etlik-Ankara, Turkey) approved the study, and informed
consent was obtained from each subject. Between January
2005 and July 2009, 711 patients were referred to the Renal
Unit of the Gulhane School of Medicine Medical Center,
Ankara, Turkey, for the first time because of suspected or
manifest renal failure. All patients were diagnosed as hav-
ing CKD according to their estimated GFR (eGFR) and the
presence of kidney injury as defined by National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
Guidelines (19). To minimize any confounding effects of
conditions that may influence endothelial dysfunction, 366
patients who were taking drugs influencing endothelial
function were excluded, including angiotensin-converting
enzyme inhibitors (n  131), angiotensin receptor blockers
(n  100), statins (n  76), erythropoiein (n  12), or
supplemental vitamin pills (n  47). Otherwise, other ex-
clusion criteria including acute infections and unwilling-
ness to participate in the study were applied (n  21).
Eighty-eight eligible patients dropped out during observa-
tion for the following reasons: lost contact or transferred to
other dialysis units (n  32), viral hepatitis (n  6), vasc-
ulitis (n  3), and withdrew consent (n  47). In total, 257
patients with a mean age of 52 12 years were included in
the study.
The etiologies for the CKD are given in Table 1. Forty-
four of the patients were on anti-hypertensive therapy (32
patients were treated with calcium channel antagonists, 5
patients were treated with -blocker agents, 2 patients
were treated with  blockers, and 5 patients were treated
with loop diuretics). Fifty-eight of the patients were on
anti-diabetic therapy (33 patients were treated with oral
anti-diabetics and 25 patients were treated with insulin).
As soon as diabetic nephropathy was diagnosed, all pa-
tients taking oral anti-diabetics were changed to insulin.
Forty-nine patients (20%) had a history of CVD as defined
by medical history and/or clinical findings at time of en-
Table 1. Demographic and clinical characteristics of the study groups
eGFR (ml/min per 1.73
m2)
90
(Stage 1)
(n  44)
60 to 89
(Stage 2)
(n  53)
30 to 59
(Stage 3)
(n  57)
15 to 29
(Stage 4)
(n  49)
15
(Stage 5)
(n  54)
Age (years) 50 (28 to 71) 55 (30 to 69) 51 (29 to 71) 54 (31 to 71) 49 (28 to 71)
Sex (M/F) 22/22 28/25 28/29 26/23 26/28
Body mass index (kg/m2) 26.6 2.6 26.5 3.1 25.9 2.5 25.9 2.9 25.3 2.7
History of CVD (n) 11 5 9 9 15
Etiology of CKD (n)
diabetes 7 13 13 13 12
glomerulonephritis 10 8 9 6 10
hypertension 4 10 12 7 11
ADPKD 2 4 1 1 3
reflux nephropathy 1 1 2 1 2
unknown 20 17 20 21 16
Smoking, current (n) 20 25 25 19 24
Follow-up (months) 39 (25 to 42) 33 (7 to 42) 39 (5 to 42) 36 (3 to 42) 39 (2 to 43)
Deaths (n) — — — 1 1
Cardiovascular death (n) — 5 7 2 8
Nonfatal cardiovascular
event (n)
3 11 9 12 22
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rollment. Of these 49 patients, 6 had cerebrovascular dis-
ease (stroke), 35 had cardiovascular disease (acute myocar-
dial infarction, angina pectoris, or had undergone coronary
artery bypass surgery); 6 had a history of peripheral isch-
emic atherosclerotic vascular disease, and 2 had a history
of an aortic aneurysm. Smoking habits were recorded: 113
patients were former or current smokers and 144 were
nonsmokers.
Patients were classified with respect to eGFR levels from
stages 1 to 5 as determined by Kidney Disease Outcomes
Quality Initiative (Table 1), according to the simplified
version of the Modification of Diet in Renal Disease for-
mula as defined by Levey et al. (20). Patients were followed
for time-to-event analysis of cardiovascular outcomes until
cardiovascular event or death, whichever came first. Infor-
mation regarding median follow-up and events recorded
in each CKD stage is detailed in Table 1.
Laboratory Measurements
All samples were obtained from patients and controls in
the morning after 12 hours of fasting for measurement of
serum albumin, hemoglobin, total serum cholesterol (TC),
triglyceride (TG), HDL, and LDL cholesterol. Total plasma
cholesterol, TG, and HDL cholesterol were measured by
enzymatic colorimetric method with an Olympus AU 600
autoanalyzer using reagents from Olympus Diagnostics
(Hamburg, Germany). LDL cholesterol was calculated by
the Friedewald’s formula. For the measurement of high
sensitivity CRP (hsCRP), serum samples were diluted with
a ratio of 1/101 with the diluents solution. Calibrators, kit
controls, and serum samples were all added on each mi-
crowell with an incubation period of 30 minutes. After
three washing intervals, 100 l enzyme conjugate (perox-
idase labeled anti-CRP) was added on each microwell for
an additional 15-minute incubation at room temperature in
the dark. The reaction was stopped with a stop solution,
and photometric measurement was performed at the
450-nm wavelength. The amount of serum samples was
calculated as milligrams per liter with a graphic that was
made by noting the absorbance levels of the calibrators.
Plasma sTWEAK and PTX3 Measurements
Plasma PTX-3 concentration was measured a posteriori
and in duplicate from frozen samples using a commer-
cially available ELISA kit (Perseus Proteomics). The PTX3
ELISA system has a detection limit of 0.1 ng/ml, with
intra-assay and interassay coefficients of variation of 5%.
Similarly, plasma concentrations of sTWEAK were deter-
mined in duplicate with commercially available ELISA kits
(Bender MedSystems, Vienna, Austria). The minimum de-
tectable level of sTWEAK was 10 pg/ml. Intra- and inter-
assay coefficients of variation were 7.9 and 9.2%, respec-
tively.
Vascular Assessment
Vascular assessments were performed subsequent to
blood extraction. Arterial BP was measured by a physician
in the morning three consecutive times after a 15-minute
resting period, and mean values were calculated for sys-
tolic and diastolic BP in all patients.
Endothelium-dependent vasodilatation (FMD) and en-
dothelium-independent vasodilatation (nitroglycerine-me-
diated dilatation [NMD]) of the brachial artery were as-
sessed noninvasively, using high-resolution ultrasound
(21). Measurements were made by a single observer using
an ATL 5000 ultrasound system (Advanced Technology
Laboratories, Bothell, WA) with a 12-Mhz probe. The sub-
jects remained at rest in the supine position for 15 min-
utes before the examination started. The subject’s arm was
comfortably immobilized in the extended position to allow
consistent recording of the brachial artery 2 to 4 cm above
the antecubital fossa. Three adjacent measurements of end-
diastolic brachial artery diameter were made from single
two-dimensional frames. All ultrasound images were re-
corded on S-VHS videotape for subsequent blinded analysis.
A pneumatic tourniquet was inflated to 200 mmHg with
obliteration of the radial pulse. After 5 minutes, the cuff was
deflated. Flow measurements were made 60 seconds after
deflation. After a further 15 minutes, measurements were
repeated, and again 3 minutes after administration of oral
sublingual glyceryl trinitrate (400 g). The maximum FMD
and NMD dilation diameters were calculated as the aver-
age of the three consecutive maximum diameter measure-
ments. The FMD and NMD were calculated as the percent
change in diameter compared with baseline resting diam-
eters.
IMT was assessed in all subjects, Briefly, a high-resolu-
tion B-mode ultrasound of the common carotid arteries with
scanning of the longitudinal axis until the bifurcation and of
the transversal axis was performed using an instrument gen-
erating awide band ultrasonic pulse with amiddle frequency
of 12 MHz (ATL 5000; Advanced Technology Laboratories).
For each carotid artery, two longitudinal measurements were
obtained by rotating the vessels at 180° increments along their
axis. All patients and controls were blindly examined by one
experienced operator (the intraoperator variability was 4%).
IMT was measured at 1 cm proximal to the bifurcation on
each side.
Statistical Analyses
All of the statistical analyses were performed using the
SPSS 11.0 (SPSS, Chicago, IL) statistical package. Non-
normally distributed variables were expressed as median
(range), and normally distributed variables were expressed
as mean  SD. Between-group comparisons were assessed
for nominal variables with the 2 test and by Kruskal-
Wallis test (ANOVA). Spearman’s rank correlation was
used to determine correlations between variables. Stepwise
multivariate regression analysis was used to assess the
predictors for FMD and IMT levels. Time-to-event analysis
of cardiovascular outcomes was done using the Cox pro-
portional hazards model, including adjustment for poten-
tial confounding factors. Data are presented in the form of
hazard ratios and 95% confidence intervals.
Results
The demographic and clinical characteristics of the study
groups are given in Table 1. There were no statistically
significant differences among the different CKD stages with
regard to age, gender, body mass index, history of CVD,
etiology of CKD, and smoking status.
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Biochemical and vascular assessments are given in
Table 2. Serum albumin, calcium, sTWEAK, and FMD
levels gradually decreased across increasing CKD stages,
whereas serum phosphate, intact parathyroid hormone,
hsCRP, PTX levels, and IMT values increased. Box plots
showing the decrease of TWEAK and increase of PTX3
levels in parallel with the reduction in eGFR are given in
Figure 1. Neither PTX3 (7.8  7.3 versus 7.9  8.2 ng/ml;
n  49/208) nor sTWEAK (239  99 versus 255  107
pg/ml; n  49/208) concentrations varied between pa-
tients with or without previous CVD. However, PTX3 was
higher (12.4  8.0 versus 6.5  5.9 ng/ml; P  0.001; n 
58/199) and TWEAK was lower (220 99 versus 261 106
pg/ml; n  49/208) in patients with comorbid diabetes.
Univariate and multivariate associates of FMD and IMT
are given in Table 3. Significant determinants of FMD were
sTWEAK, hsCRP, PTX3, NMD, systolic BP, diabetes, albu-
min, iPTH, and eGFR. Significant determinants on IMT
were only iPTH and eGFR. Because it could be argued that
these biomarkers may be collinear with CRP determina-
tions, we repeated the models excluding CRP measure-
ments. Results remained the same (data not shown). Ad-
ditionally, we repeated the models excluding diabetics; the
results remained the same (data not shown).
Cardiovascular outcomes were determined from the day
of examination onward, with a mean follow-up period of
39 months (range, 2 to 43 months). Twenty-four patients
died; 22 died from cardiovascular causes and 2 died from
malignancies. Causes of cardiovascular death were coro-
nary heart disease (n  13), sudden death (n  4), stroke
(n 3), or complicated peripheral vascular disease (n 2).
Because only 24 fatal events were registered, we did not
study multivariate Cox adjustment because of the likeli-
hood of model overfitting. During the follow-up period, 57
additional nonfatal cardiovascular events were registered
as follows: stroke (n 13); myocardial infarction or related
(n  33); peripheral vascular disease (n  7), and aortic
aneurysm (n  4).
The predictors for time-to-cardiovascular event (n  79,
including a composite of fatal and nonfatal) were studied by
univariate and multivariate COX analysis (Table 4). In uni-
variate COX, sTWEAK, PTX3, FMD, and hsCRP were signif-
icant predictors of outcome. Multivariate COX was used to
study the impact of these variables in pairs or together, con-
sidering the additional adjustment for age, gender, eGFR,
diabetes, and cardiovascular comorbidity. We first studied
sTWEAK levels (Table 4), whereby decreasing sTWEAK con-
centration was associated with increased risk of cardiovascu-
lar events independently of basic confounders (model 1) and
FMD (model 2). On the other hand, circulating levels of PTX3
(Table 4) were directly associated with cardiovascular out-
comes, independent of confounders and its analogous hsCRP
(model 1), but this association was lost after adjustment for
FMD (model 2).
Discussion
This observational cohort study provides a comprehen-
sive overview of the evolution of sTWEAK and PTX3
levels in patients with progressive kidney failure. PTX3
was initially described as an early marker of innate immu-
nity and inflammatory responses (22), being highly ex-
pressed in atherosclerotic lesions and in patients with un-
stable angina pectoris (12,23,24). Additionally, it was
recently shown that HDLs specifically upregulate PTX3
expression through the PI3K/Akt pathway without affect-
ing its homologous CRP (25). Studies in gene-modified
mice showed that PTX3 has complex, nonredundant func-
tions in vivo, ranging from the assembly of a hyaluronic
acid–rich extracellular matrix and female fertility to innate
immunity against diverse microorganisms (10,26). Along this
line, our study showed the possible role of PTX3 on local
vascular health in nondialysis CKD as assessed by FMD (9).
Expanding our previous observations on PTX3 and mor-
tality prediction in incident and prevalent dialysis popu-
lations (13,14), increased PTX3 levels predicted cardiovas-
cular outcomes in our study, independently of traditional
risk factors and of its homologous CRP. The role of PTX3 as
a marker of endothelial function in CKD can be supported
by the fact that multivariate adjustment for FMD made the
predictive performance of PTX3 disappear in our COX
analysis. PTX3 has also been detected in atherosclerotic
lesions and has been implicated on neointimal thickening
plaques (17,27,28). However, the recent observation that
double knockout mice lacking ApoE and PTX3 showed an
increment in aortic lesion size and a higher inflamma-
tory response compared with ApoE knockout mice ex-
pressing PTX3 (29) has lead to hypotheses that PTX3 may be
a failed compensatory mechanism to endothelial damage. In
this regard, neither PTX3 nor sTWEAK levels explained the
IMT variance in multivariate analysis, despite both molecules
being present in atheromatous plaques (16,17). Recent stud-
ies have suggested that, in nondialysis CKD patients,
other etiologies than atherosclerosis (such as fluid over-
load) may be more important in determining IMT levels
(18). This is supported by reports in healthy individuals
indicating that wall shear stress may be an important
determinant of IMT (30).
sTWEAK was originally identified as a soluble protein
that ex vivo was released in lower amounts from injured
vessels than from healthy vessels (16). In previous obser-
vations (7) and in this study, the decline in eGFR was
accompanied by gradual reductions both in sTWEAK
plasma levels and FMD, both assessments being strongly
interrelated and likely suggesting a link between sTWEAK
and endothelial dysfunction in CKD patients. Now we add
to this evidence that reduced FMD and decreased
sTWEAK levels are independent predictors of future car-
diovascular outcomes in nondialysis CKD patients. This
observation is consistent with recent survival data from
patients with stable heart failure (31). As expected from the
progressive reduction in sTWEAK with decreasing eGFR,
sTWEAK is low in hemodialysis patients (8). In such pa-
tients, we reported, however, that increased sTWEAK as-
sociated with a higher probability of death (8). A possible
explanation for these contradictory findings may lie within
the existence of competing risks (or the so-called reverse
epidemiology phenomenon) in CKD patients, whereby the
presence of certain risk factors in uremia, mainly inflam-
mation and protein-energy wasting, overrides and re-
verses the natural course and actions of other risk biomark-
ers (32,33). The pathologic effects of TWEAK observed in
animal experimental models (34–36) are mediated by the
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binding of sTWEAK with its receptor Fn14. Fn14 expres-
sion is practically absent in healthy human aortic wall but
is highly increased under pathologic conditions (37). A
pro-inflammatory environment increases Fn14 expression
(35,36) but also allows CD163 to sequester and degrade
sTWEAK by acting as a scavenger receptor (38), thus pre-
venting Fn14 binding (39). On the basis of this preceding
literature, we speculate that the reduction in sTWEAK
concentrations across CKD stages observed in our cross-
sectional study could potentially reflect either of these two
processes.
Strengths of this study are the relatively large sample
size of uniformly distributed etiologically diagnosed CKD
patients across the different disease stages, together with
the exclusion of drugs that may confound the interpreta-
tion of the eGFR–vascular health axis. At the same time,
however, and because of these medical exclusions, our
data are not necessarily representative of the normal non-
dialysis CKD population. This may translate, for instance,
into a relatively young cohort and over-representation of
certain etiologies. The use of continuous variables reduces
residual confounding in our analysis. However, we cannot
Figure 1. | Box plots showing the decrease in TWEAK (A) and increase in PTX3 (B) levels in parallel with the reduction in eGFR.
Table 3. Univariate and multivariate associates of flow-mediated dilatation (FMD) and intima-media thickness (IMT)
Parameter
FMD IMT
Univariatea

Multivariateb
 (P)
Univariatea

Multivariatec
 (P)
FMD (%) — — 0.64 NS
IMT (mm) 0.64 NS — —
sTWEAK (pg/ml) 0.63 0.10 (0.02) 0.54 NS
hsCRP (mg/l) 0.58 0.10 (0.03) 0.59 NS
PTX3 (ng/ml) 0.59 0.09 (0.02) 0.49 NS
NMD (%) 0.43 0.10 (0.007) 0.29 NS
Age (years) NS NS NS NS
Gender (men/women) — NS NS NS
Diabetes (yes/no ) — 0.11 (0.03) 0.16 NS
History of CVD (yes/no) — NS NS NS
Smoking (yes/no) — NS NS NS
Body mass index (kg/m2) NS — NS —
SBP (mmHg) 0.13 0.07 (0.04) NS —
Serum albumin (g/dl) 0.18 0.09 (0.007) 0.16 —
24-hour proteinuria (mg/day) NS NS 0.13 NS
Serum calcium (mg/dl) 0.46 NS 0.44 NS
Serum phosphate (mg/dl) 0.61 NS 0.54 NS
iPTH (pg/ml) 0.79 0.19 (0.008) 0.69 0.17 (0.04)
eGFR (ml/min) 0.82 0.47 (0.001) 0.74 0.60 (0.001)
Variables known to influence FMD levels (age, gender, diabetes, history of CVD, smoking, IMT, hsCRP, NMD, SBP, albumin, 24-
hour proteinuria, Ca, P, iPTH, and eGFR) and IMT levels (age, gender, diabetes, history of CVD, smoking, FMD, hsCRP, NMD,
24-hour proteinuria, Ca, P, iPTH, and eGFR) were initially included in the multivariate analyses. NS, not significant; SBP,
systolic BP.
aStatistically significant (P  0.05)  values as assessed by Spearman Rank’s test. The r2 of the multivariate models were b0.75 and
c0.56.
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exclude the possibility of other unknown confounders.
Finally, it can be argued that eGFR is subject to inaccura-
cies in CKD classification. We included, nonetheless, etio-
logically diagnosed patients, and eGFR was always treated
as a continuous variable in all our analyses.
Ultimately, our interest in these molecular pathway rep-
resentatives relates to their potential as therapeutic targets
(40). In this regard, short-term angiotensin-converting en-
zyme inhibitor treatment significantly improved endothe-
lial function and normalized both PTX3 and urinary pro-
tein excretion in type 2 diabetic proteinuric patients (41).
Also, the improvement in FMD after combined therapy
with the renin–angiotensin system and calcium channel
blockers was independently associated with both PTX3
and sTWEAK normalization in type 2 diabetic hyperten-
sive patients (42). Hence, this study concluded that both
PTX3 and sTWEAK levels strongly associate with the en-
dothelial dysfunction typically observed with progressive
kidney failure. Additionally, both biomarkers impacted the
predictability of cardiovascular outcomes; in the case of
PTX3, this was done dependently on FMD levels, and in
the case of sTWEAK, it was independent of such vascular
derangements. This and other existing evidence may en-
courage further mechanistic research regarding the poten-
tial of these molecules as therapeutic targets in inflamma-
tion- or atherosclerosis-related diseases.
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